Document:

EX-10.1

 Exhibit 10.1 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause
competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. 
 AMENDMENT #1 

TO SUITE RETENTION AND DEVELOPMENT AGREEMENT 

THIS AMENDMENT #1 (the “Amendment”) to the SUITE RETENTION AND DEVELOPMENT AGREEMENT dated September 9, 2019 (the
“Agreement”) is made and entered into as of September 22, 2020 (the “Amendment Effective Date”), by and between Albany Molecular Research, Inc. with a place of business at 26 Corporate Circle, Albany, New York 12203
(“AMRI”) and Translate Bio, Inc. with a place of business at 29 Hartwell Avenue, Lexington, Massachusetts 02421 (“Translate Bio”). For purposes of this Amendment, AMRI and Translate Bio are each a “Party” and
collectively, the “Parties.” 
 WHEREAS, Translate Bio has requested that AMRI use the Cleanroom Suites to perform additional
services relating to the manufacture of Translate Bio’s bulk drug product, and AMRI has agreed to perform such additional services; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 

AMENDMENTS 
  

	1.1	 Article I of the Agreement is hereby amended to add the following definitions (in alphabetical order, as
applicable): 

  

	 	(a)	 “Build-Out Completion” means August 31, 2020.

  

	 	(b)	 “Bulk Drug Product” means the bulk drug product after Processing by AMRI in accordance with the
Master Batch Record. For the avoidance of doubt, unless expressly agreed by the Parties in writing the Processing of Bulk Drug Product pursuant to this Agreement shall in no event include Secondary Packaging. 

 

	 	(c)	 “Bulk Drug Product-Specific Program Technology” means any Program Technology that constitutes an
improvement, modification, derivative, or new use of the Raw Materials proprietary to Translate Bio or a Translate Bio partner or of the Drug Product, including without limitation the manufacturing process for Drug Product as set forth in the Master
Batch Record, but which is not an improvement of general applicability to the manufacturing process, and all intellectual property rights in any of the foregoing. 

	 	(d)	 “Bulk Drug Product Specifications” means the written specifications and quality standards, including
tests, analytical procedures and acceptance criteria, that are established to confirm the characteristics and quality of the Bulk Drug Product as set forth in the mutually agreed upon Master Batch Record, and as amended from time to time, by written
agreement of the Parties when applicable, in accordance with the procedures set forth in this Agreement and the Quality Agreement. 

  

	 	(e)	 “Packaging” of Bulk Drug Product means the filling of vials or other receptacles, as applicable, and
bulk packaging of naked vials or other receptacles, as applicable, into containers. For the avoidance of doubt, this shall exclude vial labeling and Secondary Packaging. 

 

	 	(f)	 “Process,” “Processed,” or “Processing” means (i) as relates to Drug
Substance, the conversion of the Raw Materials into Drug Substance in accordance with the Master Batch Record and the terms and conditions set forth in this Agreement and the Quality Agreement, and (ii) as relates to Bulk Drug Product, the
compounding, processing, formulating and/or Packaging of the Drug Substance and Raw Materials into Bulk Drug Product in accordance with the Master Batch Record and the terms and conditions set forth in this Agreement and the Quality Agreement.

  

	 	(g)	 “Secondary Packaging” means all packaging components or packaging activities not specifically
included under the definition for Packaging, which activities are not and will not be in direct contact with the dosage form. (For the avoidance of doubt, Secondary Packaging shall include the finished labelling of vials containing the Bulk Drug
Product). 

  

	 	(h)	 “Translate Bio Materials” means certain Raw Materials and any other materials (such as consumables)
which Translate Bio shall supply to AMRI, as mutually agreed by the Parties. Translate Bio Materials shall include Drug Substance which is Delivered by AMRI to Translate Bio (as defined in Section 5.1 herein) or which is manufactured by a third
party and provided to AMRI by or on behalf of Translate Bio. 

  

	 	(i)	 “Translate Bio Technology” means Translate Bio Existing Technology, Drug-Substance-Specific Program
Technology and Bulk Drug Product-Specific Program Technology. 

  

	1.2	 Article I of the Agreement is hereby amended to delete the definition of Drug Substance Warranty.

  

	1.3	 The first section of Section 2.1 is hereby replaced in its entirety with the following:

 In connection with this Agreement, AMRI and Translate Bio shall arrange for the design and construction of a series of
cleanroom suites and warehouse space at the Facility, as more specifically described in Exhibit A (the “Cleanroom Suites”). Title to, and risk of loss of, the Cleanroom Suites shall be retained by AMRI. AMRI shall

  
 2 

 
enter into the Detailed Design Contract and the Construction Contract, pursuant to which the design and construction, respectively, of the Cleanroom Suites (the
“Build-Out”) shall be conducted in conformance with Translate Bio’s requirements (as mutually agreed by the Parties) and the terms of and conditions of this Agreement. The Parties agree that the
Build-Out, and specifically design of the Cleanroom Suites, shall be a joint effort between the Parties who shall share responsibility in ensuring that the Cleanroom Suites satisfy Translate Bio’s
objectives. For clarity, the rights of Translate Bio set forth in Section 2.7 of the Agreement shall apply with respect to the warehouse space funded by the Translate Bio Capital Investment, provided that AMRI shall be able to use unoccupied
ambient space within the warehouse for temporary storage of consumables unrelated to mRNA manufacture, but shall make such space available as needed for Translate Bio purposes. 

 

	1.4	 Section 2.8(d) is hereby replaced in its entirety with the following: 

(i) Monthly Payment. On a monthly basis during the Term, beginning with the month immediately following the Build-Out Completion, Translate Bio shall have an obligation to pay AMRI an amount equal to (a) one million U.S. Dollars ($1,000,000) (as may be increased pursuant to the immediately following paragraph, the
“Translate Bio Monthly Fee”), plus (b) the Incremental Monthly Fee (as defined in Section 3.2), if any (the Translate Bio Monthly Fee and the Incremental Monthly Fee , collectively, the “Aggregate Monthly Payment”).
Translate Bio shall owe a pro-rated payment for the month during which the Build-Out Completion occurs, equivalent to: the Translate Bio Monthly Fee (i) divided by
the number of days in such month, and (ii) multiplied by the number of days remaining in such month following the day of the month that Build-Out Completion occurred (inclusive of such day). The Parties
agree that the Translate Bio Monthly Fee shall be made to AMRI in exchange for the Suite Retention and the Development Services (excluding any Batches covered by the Incremental Monthly Fee and any services expressly set forth in Exhibit D, which
shall be subject to the charges set forth therein). Notwithstanding the foregoing, the Parties agree that Translate Bio shall be obligated to pay the Translate Bio Monthly Fee, irrespective of whether AMRI is providing Development Services during
the relevant monthly period, Furthermore, the Translate Bio Monthly Fee is not refundable or transferrable, and is not creditable to any future services or periods covered by this Agreement. 

AMRI may implement an increase in the Translate Bio Monthly Fee once annually, beginning on January 1 of each calendar year following the
first anniversary of Build-Out Completion, in an amount equal to three percent (3%) of the then-current Translate Bio Monthly Fee. AMRI shall provide Translate Bio with written notice of any such increase at
least [**] prior to its effective date. 
 (ii) Invoicing and Payments. 

 

	 	(a)	 Translate Bio Monthly Fee. AMRI shall provide an invoice to Translate Bio for the Translate Bio Monthly Fee
[**] prior to the first day of the applicable month, and Translate Bio shall make payment of such Translate Bio Monthly Fee on the first Business Day of such month. 

  
 3 

	 	(b)	 Incremental Monthly Fee. AMRI shall provide an invoice to Translate Bio for the Incremental Monthly Fee, if
any, as soon as possible after the number of Batches of Drug Substance and/or Bulk Drug Product that AMRI completed during such month are known, which shall in no case be earlier than the end of such month. Translate Bio shall make payment of such
Incremental Monthly Fee within [**] of receipt of such invoice. 

 (iii) Forecast and Purchase Orders. 

 

	 	(a)	 Forecast. On the first day of each calendar month, beginning approximately [**] prior to the date of Build-Out Completion, Translate Bio shall furnish to AMRI a written [**] rolling forecast of quantities of Drug Substance and/or Bulk Drug Product Batches that Translate Bio intends to order from AMRI during such
period. 

  

	 	(b)	 Purchase Orders. For purchase orders relating to the Translate Bio Monthly Fee, upon Build-Out Completion, Translate Bio shall provide a purchase order to AMRI for Translate Bio Monthly Fees for the period from Build-Out Completion (pro-rated for the month in which Build-Out Completion occurs) through the end of the calendar year. Thereafter on an annual basis, [**] prior to the start of each calendar
year, Translate Bio shall provide a purchase order to AMRI for Translate Bio Monthly Fees for the following calendar year (January 1 through December 31). 

  

	1.5	 The third sentence of Section 3.1 is hereby replaced in its entirety with the following:

 Translate Bio is obligated to pay for (via the Translate Bio Monthly Fee, the Incremental Monthly Fee and any applicable
additional costs per Section 2.8(e)), and AMRI shall have no liability for, all Development Services even if the Drug Substance and/or Bulk Drug Product produced does not conform to the Drug Substance Specifications or Bulk Drug Product
Specifications, respectively, unless such non-conformity is attributable to AMRI’s gross negligence or willful misconduct. 
  

	1.6	 Section 3.2 is hereby replaced in its entirety with the following: 

Monthly Batches and Pricing. As set forth in Section 2.8(d)(iii)(a), Translate Bio shall specify the number of Batches of Drug
Substance and/or Bulk Drug Product to be Processed by AMRI in any given calendar month. Pricing for such Batches shall be as follows (as may be increased pursuant to this Section 3.2, the “Batch Pricing”): 

 

					
	 Batch of Drug Substance
	  	$	[**]	 
	 Batch of Bulk Drug Product
	  	$	[**]	 

 The Batch Pricing set forth in the table above assumes: (i) operation of the Cleanroom Suites for no more
than eight hours per day, five days per week, (ii) that each Batch of Drug Substance shall take [**] to Process and each Batch of Bulk Drug Product shall 

  
 4 

 
take [**] to Process, and (iii) Batch size of Drug Substance equal to [**], and Batch size of Drug Product equal to the liposomal encapsulation of one Batch of Drug Substance. AMRI shall
only be obligated to Process the number of Batches of Drug Substance and/or Bulk Drug Product permitted by such one-shift operations during each month. The Parties agree that, [**] from the Amendment Effective
Date, the Parties will negotiate in good faith any increase or decrease in the Batch Pricing in the event that the actual Processing time for a Batch of Drug Substance and/or a Batch of Bulk Drug Product is longer or shorter than the estimates set
forth above. 
 AMRI may implement an increase in the Batch Pricing once annually, beginning on January 1 of each calendar year
following the first anniversary of Build-Out Completion, in an amount equal to three percent (3%) of the then-current Batch Pricing. AMRI shall provide Translate Bio with written notice of any such increase at
least [**] prior to its effective date. 
 On a monthly basis, Translate Bio shall owe to AMRI the greater of (i) the Translate Bio
Monthly Fee, or (ii) the aggregate amount due for all Batches of Drug Substance and Bulk Drug Product completed during such month (any amount over $1,000,000 shall be referred to as the “Incremental Monthly Fee”). For purposes of this
provision, completion of a Batch shall mean that AMRI has fulfilled its Processing obligations (which, for the avoidance of doubt, shall not include testing or release). 

By way of example: 
  

	 	(a)	 If AMRI completes Processing of [**] of Drug Substance and [**] of Bulk Drug Product in a month, Translate Bio
shall owe the Translate Bio Monthly Fee [**]. 

  

	 	(b)	 If AMRI completes Processing of [**] of Drug Substance and [**] of Bulk Drug Product in a month, Translate Bio
shall owe the Translate Bio Monthly Fee [**]. 

  

	1.7	 Section 3.3 is hereby replaced in its entirety with the following: 

Rescheduling and Cancellation. In the event that Translate Bio, with less than [**] notice prior to the scheduled date of manufacture,
cancels, or delays or reschedules by more than [**], any Batches for a month in which there is an Incremental Monthly Fee (based on the forecast provided in Section 2.8(d)(iii)(a)), Translate Bio shall pay an amount equal to [**] percent
([**]%) of the applicable Incremental Monthly Fee. By way of example: 
  

	 	(a)	 if AMRI is scheduled to Process [**] of Drug Substance and [**] of Bulk Drug Product in a month and Translate
Bio cancels or reschedules [**] of Drug Substance, Translate shall owe $[**]. 

  
 5 

	 	(b)	 if AMRI is scheduled to Process [**] of Drug Substance and [**] of Bulk Drug Product in a month and Translate
Bio cancels or reschedules [**] of Bulk Drug Product, Translate shall owe $[**]. 

 For the avoidance of doubt, this
Section 3.3 shall in no event limit Translate Bio’s obligation to pay the Translate Bio Monthly Fee each month. 
  

	1.8	 The first sentence of Section 4.1 of the Agreement is hereby replaced in its entirety with the following:

 Translate Bio shall supply to AMRI for Processing, at Translate Bio’s sole cost, the Translate Bio Materials. 

 

	1.9	 Article 5 of the Agreement is hereby replaced in its entirety with the following: 

5.1 Delivery of Drug Substance and/or Bulk Drug Product. Title and risk of loss of Drug Substance, Bulk Drug Product and
other deliverables shall transfer from AMRI to Translate Bio upon delivery EXW Facility (Incoterms 2010) (“Delivery”). For manufactured Batches of Bulk Drug Product, Delivery shall occur upon the later of (a) the issuance to Translate
Bio of the completed Batch Documentation, in accordance with the Quality Agreement and (b) notification by AMRI to Translate Bio that the Batch is available for pick up at Facility. For manufactured Batches of Drug Substance, Delivery shall
occur upon the issuance to Translate Bio of the completed Batch Documentation, in accordance with the Quality Agreement. Translate Bio is responsible for transportation of the Bulk Drug Product to Translate Bio’s final destination, at the sole
risk and expense of Translate Bio. In the event that Translate Bio elects for Drug Substance Processed by AMRI not be used to Process Bulk Drug Product pursuant to this Agreement, Translate Bio is responsible for transportation of the Drug Substance
to Translate Bio’s final destination, at the sole risk and expense of Translate Bio. For avoidance of doubt, in each case, Translate Bio is responsible for arranging pick up by carrier and all shipping costs and risks. Should Translate Bio
request AMRI to assist with any arrangements with the carrier, such arrangements will be made by AMRI on behalf of Translate Bio in accordance with Translate Bio’s applicable instructions and at the sole risk and expense of Translate Bio. 

5.2 Storage. 

(a) Bulk Drug Product. If Translate Bio does not pick up Bulk Drug Product after AMRI has notified Translate Bio in
writing that it is available, AMRI shall store such Bulk Drug Product at the Facility. For all Bulk Drug Product stored by AMRI following Delivery, Translate Bio agrees that: (i) Translate Bio has title and risk of ownership,
(ii) Translate Bio has made a fixed commitment to purchase such Bulk Drug Product, (iii) Translate Bio is responsible for any decrease in market value of such Bulk Drug Product that relates to factors and circumstances outside of
AMRI’s control, and (iv) Translate Bio is responsible for obtaining insurance for such Bulk Drug Product during the storage period, if desired. 

  
 6 

 (b) Drug Substance. For all Drug Substance that has been Processed by
AMRI and which has not yet been used for Processing of Bulk Drug Product or which Translate Bio has elected not be used to Process Bulk Drug Product pursuant to this Agreement, AMRI shall store such Drug Substance at the Facility. For all Drug
Substance stored by AMRI following Delivery, Translate Bio agrees that: (i) Translate Bio has title and risk of ownership, (ii) Translate Bio has made a fixed commitment to purchase such Drug Substance, (iii) Translate Bio is
responsible for any decrease in market value of such Drug Substance that relates to factors and circumstances outside of AMRI’s control, and (iv) Translate Bio is responsible for obtaining insurance for such Drug Substance during the
storage period, if desired. 
 (c) Storage fees. The storage fees outlined in Exhibit D do not apply if storage of
Drug Substance or Bulk Drug Product is within the warehouse space indicated as part of the “Cleanroom Suite” referenced in Exhibit A. For clarity, the Parties agree that such storage fees shall apply to storage of Drug Substance and/or
Bulk Drug Product in the event that the warehouse space indicated as part of the Cleanroom Suite is full. 
  

	1.10	 Section 7.1(c) is hereby replaced in its entirety with the following: 

 

	 	(c)	 all Drug Substance and/or Bulk Drug Product delivered hereunder shall be manufactured in accordance with cGMP,
the then-current Master Batch Record and the Quality Agreement, and, if manufactured after establishment of a validated manufacturing process, shall conform to the Drug Substance Specifications and/or Bulk Drug Product Specifications, as applicable,
upon Delivery; 

  

	1.11	 Section 10.1 is hereby replaced in its entirety with the following: 

Indemnification by AMRI. AMRI shall defend (upon Translate Bio’s written request), indemnify and hold harmless
Translate Bio, its Affiliates, and their respective directors, officers, employees and agents (“Translate Bio Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including
reasonable attorneys’ fees) resulting from or arising out of any suit, demand or action by any third party (“Losses”) to the extent (i) caused by the gross negligence or willful misconduct of any AMRI Indemnitee;
(ii) arising from a claim by a third party that AMRI Technology used in the performance of the Development Services or Process (on its own and not in combination with any Translate Bio Materials or Translate Bio Technology) infringes such third
party’s intellectual property right; or (iii) caused by the breach of any of AMRI’s representations, warranties (including without limitation the representations made in Section 7.1(c) herein) or obligations under this Agreement,
in each case relating to the Development Services only; except to the extent of the amount of any Losses arising out of claims for which Translate Bio is obligated to indemnify AMRI hereunder. 

  
 7 

	1.12	 The second sentence of Section 8.1 is hereby amended in its entirety as follows: 

Confidential Information of Translate Bio includes, but is not limited to Translate Bio Existing Technology, Drug Substance-Specific Program
Technology, Bulk Drug Product-Specific Program Technology, the Master Batch Record, the Drug Substance Specifications and the Bulk Drug Product Specifications. 
  

	1.13	 The first sentence of Section 9.3 is hereby amended in its entirety as follows: 

All Drug Substance-Specific Program Technology and Bulk Drug Product-Specific Program Technology shall be the exclusive property of Translate
Bio, and AMRI shall and hereby does assign all of its rights, title and interest in and to the Drug Substance-Specific Program Technology and the Bulk Drug Product-Specific Program Technology to Translate Bio, and shall take such actions as are
reasonably requested by Translate Bio, at Translate Bio’s expense, to effect the foregoing assignment and in connection with Translate Bio’s efforts to secure patent protection for such Drug Substance-Specific Program Technology and Bulk
Drug Product-Specific Program Technology. 
  

	1.14	 Except for those provisions of the Agreement referenced in Sections 1.3 through 1.13 above (which shall be as
expressly set forth above), all references in the Agreement to “Drug Substance” shall become references to “Drug Substance and/or Bulk Drug Product, as applicable” and all references to “Drug Substance Specifications”
shall become references to “Drug Substance Specifications and/or Bulk Drug Product Specifications, as applicable.” 

  

	1.15	 The Parties expressly agree that the references to Drug Substance in the Agreement, solely as relates to its
use in the Processing of Bulk Drug Product, shall include (i) Drug Substance Processed by AMRI pursuant to the Agreement, or (ii) drug substance which is otherwise manufactured by or on behalf of Translate Bio and provided to AMRI (the
“Third Party Drug Substance”). For the avoidance of doubt, Translate Bio’s obligations with respect to Translate Bio Materials, as set forth in Section 4.1 of the Agreement, shall apply to any Third Party Drug Substance. The
Parties further agree that AMRI’s obligations with respect to any testing of the Third Party Drug Substance shall only be as expressly agreed by the Parties in writing. Notwithstanding the foregoing, AMRI shall not be responsible for any
defects in the Third Party Drug Substance. 

  

	1.16	 In Exhibit B, the table labeled “Translate Bio Equipment” is hereby replaced in its entirety with the
table labeled with same name in Exhibit B-1 attached hereto. 

  

	1.17	 The Parties agree that promptly following the Amendment Effective Date, they will prepare a matrix which sets
forth the raw materials and consumables to be provided by each of Translate Bio and AMRI with respect to both the Drug Substance and the Bulk Drug Product (provided that Drug Substance shall constitute Translate Bio materials, even if not included
on such matrix). Once both Parties have approved in writing, such 

  
 8 

	 	
matrix shall be binding provided that the Parties may mutually agree to change the allocation of procurement responsibilities between the Parties for such materials in writing [**] period
following the Amendment Effective Date. For clarity, in the event new materials are required with respect to the Processing of Drug Substance and/or Bulk Drug Product or any new products are added to this Agreement, those changes will be managed
through the appropriate quality and operational systems (e.g., tech transfer, change control) on a timely basis as required for the Parties to perform their responsibilities pursuant to this Agreement. 

 

	1.18	 Article 14 is hereby amended as follows: 

The “To AMRI” notice is amended and restated as follows: 

Albany Molecular Research, Inc. 

26 Corporate Circle 
 Albany, New
York 12212 
 Attn: Steve Lichter 

ARTICLE II 

MISCELLANEOUS 
  

	2.1	 All capitalized terms used but not defined herein shall have the meaning set forth in the Agreement.

  

	2.2	 Except as expressly set forth herein, the amendments provided herein shall not, by implication or otherwise,
limit, constitute a waiver of, or otherwise affect the rights and remedies of AMRI or Translate Bio under the Agreement, nor shall it constitute a waiver of any default, nor shall it alter, modify, amend or in any way affect any of the terms,
conditions, obligations, covenants or agreements contained in the Agreement. The amendments provided herein shall apply and be effective only with respect to the provisions of the Agreement specifically referred to by such amendments and all other
terms and conditions in the Agreement shall remain in full force and effect and are hereby ratified and confirmed. 

  

	2.3	 This Amendment may be executed in two (2) or more counterparts, each of which will be deemed an original,
but all of which together will constitute one (1) and the same instrument. Any photocopy, PDF or electronic reproduction of the executed Amendment shall constitute an original. 

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Amendment Effective Date. 

  
 9 

									
	ALBANY MOLECULAR RESEARCH, INC.	 		 	TRANSLATE BIO, INC.
					
	By:	 	 /s/ Steve Lichter
	 		 	By:	 	 /s/ Paul Burgess

					
	Name:	 	 Steve Lichter
	 		 	Name:	 	 Paul Burgess

					
	Title:	 	 President
	 		 	Title:	 	 COO and CLO

  
 10Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. 
​

Exhibit 10.1
PERFORMANCE UNIT AGREEMENT
PURSUANT TO THE
WIDEOPENWEST, INC. 2017 OMNIBUS INCENTIVE PLAN
*  *  *  *  *
Participant: [●]​ ​
Grant Date: [●]​ ​
Target Number of 
Performance Units Granted: [●]​ ​  of which:
__________ are subject to the EBITDA performance criteria, as described in Section 3(a) (the “Target EBITDA Units”); and 
__________ are subject to the Relative TSR performance criteria as described in Section 3(b) (the “Target TSR Units”).
*  *  *  *  *
THIS PERFORMANCE UNIT AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between WideOpenWest, Inc., a corporation organized in the State of Delaware (the “Company”), and the Participant specified above, pursuant to the WideOpenWest, Inc. 2017 Omnibus Incentive Plan, as in effect and as amended from time to time (the “Plan”), which is administered by the Committee; and 
WHEREAS, it has been determined under the Plan that it would be in the best interests of the Company to grant Performance Units provided herein to the Participant; and
WHEREAS, in consideration of the Grant as defined herein, Participant agrees to abide by each of the covenants set forth in this Agreement and acknowledges that the inherent value of the Grant constitutes good, valuable and sufficient consideration for each of the Participant’s covenants set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter set forth and for other good and valuable consideration, the parties hereto hereby mutually covenant and agree as follows:
	1.	Incorporation By Reference; Plan Document Receipt.  This Agreement is subject in all respects to the terms and provisions of the Plan (including, without limitation, any amendments thereto adopted at any time and from time to time unless such amendments are expressly intended not to apply to the Grant provided hereunder), all of which terms and provisions are made a part of and incorporated in this Agreement as if they were each expressly set forth herein.  Any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto in the Plan.  The Participant hereby acknowledges receipt of a true copy of the Plan and that the Participant has read the Plan carefully and fully understands its content.  In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control.  

	2.	Grant of Performance Unit Award.  The Company hereby grants to the Participant, as of the Grant Date specified above, the number of Performance Units specified above (the “Grant”).  Except as otherwise provided by the Plan, the Participant agrees and understands that nothing contained in this Agreement provides, or is intended to provide, the Participant with any protection against potential future dilution of the 

​

​

		Participant’s interest in the Company for any reason, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of any such shares, except as otherwise specifically provided for in the Plan or this Agreement.  The Participant shall not have the rights of a stockholder in respect of the Performance Units underlying this Grant until such shares are delivered to the Participant in accordance with Section 4 hereof.  

	3.	Earning of Performance Units.  The Participant shall have no right or entitlement in respect of the Performance Units unless and to the extent the Performance Units become earned and vested in accordance with this Agreement.  The Performance Units shall be earned as follows:

(a)Cumulative EBITDA.  
		(i)	Performance Units based on Cumulative EBITDA performance shall be subject to the three-year cumulative EBITDA of the Company for 2020, 2021 and 2022 and shall be earned as follows:

	5

	

	

	

	​
	Threshold Goal
	Target Goal
	Maximum Goal

	Performance (% of Target EBITDA)
	95%
	100%
	105%

	Three-Year Cumulative EBITDA
	$[***] Billion 
	$[***] Billion 
	$[***] Billion or more

	EBITDA Units
	50% of Target EBITDA Units Granted
	100% of Target EBITDA Units Granted
	200% of Target EBITDA Units Granted

​
		(ii)	For performance in between the goals set forth above, the number of EBITDA Units earned will be interpolated on a straight-line basis.

		(iii)	The Participant shall forfeit the Target EBITDA Units if the Company’s three-year cumulative EBITDA for 2020, 2021 and 2022 is less than $[***] Billion.  

		(iv)	The Committee shall round, up or down to the nearest whole number, the number of earned EBITDA Units and the cumulative EBITDA, in its sole discretion provided that it calculates such measures consistently for all EBITDA Units with Grant Dates in the same year.

		(v)	Whether and the extent to which EBITDA Units become earned and vested under Section 3(a) herein will be determined by the Committee as soon as practicable in early 2023 once the Committee certifies performance and shares of Common Stock shall be delivered as set forth in Section 4 below.

		(vi)	For purposes of the Agreement, “EBITDA” shall mean Adjusted EBITDA as defined by the Company in its earnings releases furnished with the SEC from time to time (net income (loss) before net interest expense, income taxes, depreciation and amortization (including impairments), impairment losses on intangibles and goodwill, management fees to related party, the write-up or write-off of any asset, loss on early extinguishment of debt, integration and restructuring expenses and all non-cash charges and expenses (including stock compensation expense) and certain other income and expenses).  

​

2
​

​

(b)Total Shareholder Return.  
		(i)	Performance Units based on Relative TSR (the “TSR Units”) shall be subject to the total shareholder return, as defined below, of the Company compared to the Company’s peer group as set forth on Exhibit A for the performance period between January 1, 2020 and December 31, 2022. 

Total Shareholder Return = Ending Average Stock Price – Beginning Average Stock Price + Dividends / Beginning Average Stock Price.
Where the Beginning Average Stock Price is equal to the average closing stock price for the 20-trading days leading up to the first day of the performance period and Ending Average Stock Price is equal to the average closing stock price for the 20-trading days leading up and including the last day of the performance period, assuming dividends are reinvested in additional shares of stock on the ex-dividend date. 
The total shareholder return of the Company shall be compared to the total shareholder return of the Company’s peer group on a percentile rank basis, as defined below:
P = 1 – (R-1)/(N-1)
Where:
“P” represents the percentile performance.
“N” represents the number of companies in the Company peer group, including the Company
“R” represents the Company’s ranking versus the other companies in the Company’s peer group
Example: If the Company ranks 6th out of 15 companies, the performance (“P”) therefore will be in the 64th percentile.
This calculation is as follows: 0.64 = 1 – (6 – 1)/(15 – 1)
Once the relative performance has been determined, the following payout schedule shall determine how much of the target TSR Units shall be earned:  
	Performance Relative to Peers
	TSR Units

	75th Percentile and above
	200% of Target TSR Units Granted

	50th Percentile 
	100% of Target TSR Units Granted

	35th Percentile 
	50% of Target TSR Units Granted

	Below 35th Percentile
	0% of Target TSR Units Granted

​
		(ii)	For performance in between the levels set forth above, the number of TSR Units earned will be interpolated on a straight-line basis.

		(iii)	The Committee shall round, up or down to the nearest whole number, the number of earned TSR Units and the total shareholder return, in its sole discretion provided that 

3
​

​

			it calculates such measures consistently for all TSR Units with Grant Dates in the same year.

		(iv)	Whether and the extent to which TSR Units become earned and vested under Section 3(b) herein will be determined by the Committee as soon as practicable in early 2023 once the Committee certifies performance and shares of Common Stock shall be delivered as set forth in Section 4 below.

		(c)	Change in Control.  In the event a Termination of Employment by the Company without Cause or by the Participant for Good Reason within twelve (12) months after a Change in Control, EBITDA and TSR Units shall be earned and vested based on actual performance for the performance periods set forth above.  In the event of a Change in Control, if the Company’s successor does not agree to assume this Agreement, or to substitute an equivalent award or right for this Grant, and if Participant has remained continuously employed from the Grant Date to the date of the Change in Control, and does not voluntarily resign without continuing with the Company’s successor, then EBITDA and TSR Units shall be earned and vested based on actual performance from the beginning of the performance through the date of the Change in Control. The Committee shall certify performance, immediately prior to, and contingent upon, the consummation of such Change in  and shares of Common Stock shall be delivered as set forth in Section 4 below. For purposes of this Agreement, “Good Reason” shall have the meaning set forth in the Participant’s employment agreement with the Company.  

		(d)	Termination.  In the event of a Termination of Employment (i) due to the death or Disability of the Participant or (ii) the involuntary termination of the Participant by the Company without Cause, the EBITDA and TSR Units will be pro-rated based on the number of completed months of employment during the performance period divided by the 36 month performance period and the amount of EBITDA and TSR Units shall be based on actual performance during the applicable performance periods as set forth above subject to.  If a Termination of Employment occurs with Cause, all Performance Units shall be forfeited as of the date of such Termination of Employment.  If a Termination of Employment is due to the Participant’s voluntary termination of employment with the Company including resignation or retirement, all Performance Units that have not been earned and vested as of such Termination of Employment shall be forfeited.

	4.	Settlement of Performance Units.  Subject to Section 7 herein regarding withholding tax, as soon as practicable (but within 30 days) after the Performance Units becomes both earned and vested, the Company will issue and transfer to the Participant one share of Common Stock for each Performance Unit; provided, that such issuance and transfer shall in no event occur later than March 15th of the year following the date such Performance Units become earned and vested.  No fractional shares will be issued.

	5.	Non-Transferability.  The Performance Units, and any rights and interests with respect thereto, issued under this Agreement and the Plan shall not, prior to vesting, be sold, exchanged, transferred, assigned or otherwise disposed of in any way by the Participant (or any beneficiary of the Participant), other than by testamentary disposition by the Participant or the laws of descent and distribution.  Any attempt to sell, exchange, transfer, assign, pledge, encumber or otherwise dispose of or hypothecate in any way any of the Performance Units, or the levy of any execution, attachment or similar legal process upon the Performance Units, contrary to the terms and provisions of this Agreement and/or the Plan shall be null and void and without legal force or effect.

	6.	Governing Law.  All questions concerning the construction, validity and interpretation of this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the choice of law principles thereof.

	7.	Withholding of Tax.  The Company shall have the power and the right to deduct or withhold, or require the Participant to remit to the Company, an amount sufficient to satisfy any federal, state, local and foreign taxes of any kind (including, but not limited to, the Participant’s FICA and SDI obligations) which the Company, 

4
​

​

		in its sole discretion, deems necessary to be withheld or remitted to comply with the Code and/or any other applicable law, rule or regulation with respect to the Performance Units and, if the Participant fails to do so, the Company may otherwise refuse to issue or transfer any shares of Common Stock otherwise required to be issued pursuant to this Agreement.  Any minimum statutorily required withholding obligation with regard to the Participant may be satisfied by reducing the amount of cash or shares of Common Stock otherwise deliverable to the Participant hereunder.

	8.	Entire Agreement; Amendment.  This Agreement, together with the Plan, contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject matter.  

	9.	Notices.  Any notice hereunder by the Participant shall be given to the Company in writing and such notice shall be deemed duly given only upon receipt thereof by the General Counsel of the Company.  Any notice hereunder by the Company shall be given to the Participant in writing and such notice shall be deemed duly given only upon receipt thereof at such address as the Participant may have on file with the Company.

	10.	No Right to Employment.  Any questions as to whether and when there has been a Termination and the cause of such Termination shall be determined in the sole discretion of the Committee.  Nothing in this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries or Affiliates to terminate the Participant’s employment or service at any time, for any reason and with or without Cause.

	11.	Transfer of Personal Data.  The Participant authorizes, agrees and unambiguously consents to the transmission by the Company (or any Subsidiary) of any personal data information related to the Performance Units awarded under this Agreement for legitimate business purposes (including, without limitation, the administration of the Plan).  This authorization and consent is freely given by the Participant.

	12.	Participant Covenants.  As a condition to and in consideration of Participant’s receipt of the Grant set forth in this Agreement, Participant specifically agrees to and acknowledges the reasonableness of the following employment and postemployment restrictions.

		a)	Confidential Information; Intellectual Property: Participant acknowledges and agrees that, as a result of Participant’s employment, Participant has access to trade secrets and other confidential or proprietary information of the Company and its customers and vendors (“Confidential Information”). Such information includes, but is not limited to: (i) customers and clients and customer or client lists, (ii) accounting and business methods, (iii) services or products and the marketing of such services and products, (iv) fees, costs and pricing structures, (v) designs, (vi) analysis, (vii) drawings, photographs and reports, (viii) computer software, including operating systems, applications and program listings, (ix) flow charts, manuals and documentation, (x) databases, (xi) inventions, devices, new developments, methods and processes, whether patentable or un-patentable and whether or not reduced to practice, (xii) copyrightable works, (xiii) all technology and trade secrets, and (xiv) all similar and related information in whatever form. Participant agrees that Participant shall not disclose or use at any time, either during Participant’s employment with the Company or thereafter, any Confidential Information, except to the extent that such disclosure or use is directly related to the Company’s business, or unless required to by law, or unless and to the extent that the Confidential Information in question has become generally known to and available for use by the public other than as a result of Participant’s acts or omissions to act. In addition, Participant further agrees that any invention, design or innovation that Participant conceives or devises from Participant’s use of Company time, equipment, facilities or support services belong exclusively to the Company, and that it may not be used for Participant’s personal benefit, the benefit of a competitor, or for the benefit of any person or entity other than the Company.

		b)	Non-Solicitation; Non-Competition: During Participant’s employment and for a period of twelve (12) months (the “No-Raid Period”) following Participant’s termination for any 

5
​

​

			reason Participant will not directly or indirectly solicit, induce or attempt to influence any associate to leave the employment of the Company, nor will Participant hire any such associate or assist any other person or entity in doing so (each such activity, a “Raiding Activity”). During Participant’s employment and for a period of twenty four (24) months following Participant’s termination for any reason, Participant will not, directly or indirectly, work for or contribute to the efforts of any business organization that competes, or plans to compete, with the Company or its products, nor will Participant call on or otherwise attempt (or assist the attempt) to solicit the business of any customer or client of the Company with whom Participant had direct contact or supervisory authority (each such activity, a “Competitive Activity”) in the 24-month period immediately preceding Participant’s separation (the “Non-Competition Period”). 

Participant recognizes that the existing business of the Company extends to various locations and areas throughout the United States and may extend hereafter to other countries and territories and agrees that the scope of this Paragraph 12 b) shall extend to any part of the United States, and any other country or territory, where the Company operates or conducts business, or has concrete plans to do so at the time Participant’s employment terminates. It is agreed that the Participant’s services to the Company are special and unique giving them peculiar value, the loss of which cannot be reasonably or adequately compensated for by damages, and in the event of the Participant’s breach of this Paragraph 12 b), Company shall be entitled to equitable relief by way of injunction or otherwise in addition to the cessation of payments and benefits pursuant to this Agreement or any other agreements between the Company and Participant. If any provision of Paragraph 12 b) of this Agreement is deemed to be unenforceable by a court (whether because of the subject matter of the provision, the duration of a restriction, the geographic or other scope of a restriction or otherwise), that provision shall not be rendered void but the parties instead agree that the court shall amend and alter such provision to such lesser degree, time, scope, extent and/or territory as will grant Company the maximum restriction on Participant’s activities permitted by applicable law in such circumstances. Company’s failure to exercise its rights to enforce the provisions of this Agreement shall not be affected by the existence or non-existence of any other similar agreement for anyone else employed by the Company or by Company’s failure to exercise any of its rights under any such agreement. 
		c)	Nondisparagement: Participant agrees not to make negative comments or otherwise disparage the Company or its officers, directors, employees, shareholders, agents or products and services at any time during employment or thereafter. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings). 

	13.	Compliance with Laws.  The issuance of the Performance Units or unrestricted shares pursuant to this Agreement shall be subject to, and shall comply with, any applicable requirements of any foreign and U.S. federal and state securities laws, rules and regulations (including, without limitation, the provisions of the Securities Act, the Exchange Act and in each case any respective rules and regulations promulgated thereunder) and any other law or regulation applicable thereto.  The Company shall not be obligated to issue the Performance Units or any of the shares pursuant to this Agreement if any such issuance would violate any such requirements.

	14.	Section 409A.  Notwithstanding anything herein or in the Plan to the contrary, the shares of Performance Units are intended to be exempt from the applicable requirements of Section 409A of the Code and shall be limited, construed and interpreted in accordance with such intent.

	15.	Binding Agreement; Assignment.  This Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company and its successors and assigns.  The Participant shall not assign (except in 

6
​

​

		accordance with Section 5 hereof) any part of this Agreement without the prior express written consent of the Company.

	16.	Headings.  The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.

	17.	Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.

	18.	Further Assurances.  Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as either party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.

	19.	Severability.  The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.

	20.	Acquired Rights.  The Participant acknowledges and agrees that:  (a) the Company may terminate or amend the Plan at any time; (b) the award of Performance Units made under this Agreement is completely independent of any other award or grant and is made at the sole discretion of the Company; (c) no past grants or awards (including, without limitation, the Performance Units awarded hereunder) give the Participant any right to any grants or awards in the future whatsoever; and (d) any benefits granted under this Agreement are not part of the Participant’s ordinary salary, and shall not be considered as part of such salary in the event of severance, redundancy or resignation.

​
[Remainder of Page Intentionally Left Blank]

7
​

​

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
WideOpenWest, Inc.
​
By:  
​
Name:  ​ ​​ ​________________________
​
Title:  ​ ​________________________
​
PARTICIPANT
​
‌​
Name:‌

8
​

​

​
EXHIBIT A
Peer Group
​
Additional Treatment for Peer Group Companies Throughout the Performance Period:
​
If two companies in the peer group merge, the surviving company shall remain in the peer group.  
If a company in the peer group merges with, or is acquired by, a company that is not in the peer group, and the company in the peer group is the surviving company, then the surviving company shall be included in the peer group.  
If a company in the peer group merges with, or is acquired by, a company that is not in the peer group, and the company in the peer group is not the surviving company or the surviving company is no longer publicly traded, then the surviving company shall not be included in the peer group.
If a company in the peer group declares bankruptcy, they shall remain in the peer group but be assigned a TSR of -100%. 

9
​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]